RESUMEN
BACKGROUND/AIMS: Novel agents acting against hepatitis B virus (HBV) are needed to improve HBsAg seroclearance or termed as 'functional cure'. Inarigivir (retinoic acid-inducible gene I agonist) has immunomodulatory and direct antiviral actions against HBV. We aimed to determine the safety and efficacy of Inarigivir for the treatment of HBV infection. PATIENTS/METHODS: 80 treatment-naïve patients were randomized in 4 ascending dose cohorts to receive 12 weeks of Inarigivir 25, 50, 100, 200 mg or placebo in a ratio of 4:1. All patients were then given tenofovir for another 12 weeks. RESULTS: Least squares (LS) mean reductions in HBV DNA from baseline increased with higher doses of Inarigivir (0.6116 in 25 mg and 1.5774 in 200 mg groups vs. 0.0352 in placebo group) (95% CI 0.9518-0.2011 and 1.921-1.1634 respectively). LS mean changes in HBV RNA and HBsAg from baseline ranged from -0.3856 to -0.5794 versus -0.1474 and -0.0956 to -0.1818 versus +0.0026 in Inarigivir-treated versus placebo groups respectively. During the tenofovir-treated period, LS mean reductions in HBsAg in the Inarigivir-treated groups ranged from 0.1709 to 0.3529 versus 0.1984 in the placebo group. Inarigivir-treated groups showed mean reductions in ALT from baseline between 23.3 and 33.8 versus 0.7 U/L in the placebo group. Treatment-emergent adverse events related to Inarigivir and placebo occurred in 4.7% and 6.3% patients respectively. CONCLUSIONS: Twelve-week Inarigivir up to 200 mg dose was associated with a reduction of HBV DNA, HBV RNA and antigen levels. A trend for greater HBsAg reduction was observed in Inarigivir pre-treated patients after switching to tenofovir.
Asunto(s)
Hepatitis B Crónica , Hepatitis B , Humanos , Antígenos de Superficie de la Hepatitis B , ADN Viral , Tenofovir/uso terapéutico , Antivirales/efectos adversos , Hepatitis B/tratamiento farmacológico , Virus de la Hepatitis B/genética , Antígenos e de la Hepatitis B , ARN , Resultado del TratamientoRESUMEN
Synthesis of silver nanoplates was studied in the modified polyol method, where the nucleation and seed stage occurred in a poly(ethylene glycol) (PEG)-water mixture solution, and the growth stage happened in the PEG environment. The morphological evolution of nanoplates was characterized using UV, SEM, and TEM. Interestingly, plane nanostructures with unusual jagged edges were finally formed in our modified polyol method. Using TEM, we observed the medium state of fusion between two nanoplates, resulting in generating unusual jagged edges. Therefore, a novel two-dimensional oriented attachment occurred in our modified polyol method, which involves smaller nanoplates as the building blocks. Further control experiments showed that the presence of water could break this kinetic preferred reactivity, leading to the formation of nanoparticles.
RESUMEN
RATIONALE: Pes anserine (PA) bursitis is an inflammatory condition of the medial knee. The PA bursa becomes more painful when infected, damaged, or irritated. Although various treatment options have been attempted to treat PA bursitis, optimal treatments are still debated. This study aims to investigate the effect of polydeoxyribonucleotide (PDRN) injection on reducing pain and inflammation in a patient presenting with PA bursitis. PATIENT CONCERNS: A 50-year-old female patient was admitted to our pain clinic with symptoms of tenderness and pain over the medial knee. Physical examination revealed the pain to be located over the proximal medial tibia at the insertion of the conjoined tendons of the PA. The knee had lost its range of movement and strength, and resisted knee flexion. DIAGNOSES: She was diagnosed as having PA bursitis. INTERVENTIONS: Ultrasound guided PA bursa injection was carried out. OUTCOMES: Follow-up for the patient was more than eight months. She showed good improvement in PA bursitis without any complications. LESSONS: This is the first successful report of successful PDRN injection for PA bursa.